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Abstract
Objectives:  To  compare  different  neonatal  outcomes  according  to  the  different  types  of  treat-
ments used  in  the  management  of  gestational  diabetes  mellitus.
Methods:  This  was  a  retrospective  cohort  study.  The  study  population  comprised  pregnant
women with  gestational  diabetes  treated  at  a  public  maternity  hospital  from  July  2010  to  August
2014. The  study  included  women  aged  at  least  18  years,  with  a  singleton  pregnancy,  who  met
the criteria  for  gestational  diabetes  mellitus.  Blood  glucose  levels,  fetal  abdominal  circumfer-
ence, body  mass  index  and  gestational  age  were  considered  for  treatment  decision-making.
The evaluated  neonatal  outcomes  were:  type  of  delivery,  prematurity,  weight  in  relation  to
gestational  age,  Apgar  at  1  and  5  min,  and  need  for  intensive  care  unit  admission.
Results: The  sample  consisted  of  705  pregnant  women.  The  neonatal  outcomes  were  analyzed
based on  the  treatment  received.  Women  treated  with  metformin  were  less  likely  to  have
children  who  were  small  for  gestational  age  (95%  CI:  0.09--0.66)  and  more  likely  to  have  a
newborn adequate  for  gestational  age  (95%  CI:  1.12--3.94).  Those  women  treated  with  insulin
had a  lower  chance  of  having  a  preterm  child  (95%  CI:  0.02--0.78).  The  combined  treatment  with
insulin and  metformin  resulted  in  higher  chance  for  a  neonate  to  be  born  large  for  gestational
age (95%  CI:  1.14--11.15)  and  lower  chance  to  be  born  preterm  (95%  CI:  0.01--0.71).  The  type  of
treatment did  not  affect  the  mode  of  delivery,  Apgar  score,  and  intensive  care  unit  admission.
Conclusions:  The  pediatrician  in  the  delivery  room  can  expect  different  outcomes  for  diabetic
mothers based  on  the  treatment  received.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Desfechos  neonatais  de  acordo  com  diferentes  terapêuticas  do  diabetes  mellitus
gestacional
Resumo
Objetivos:  Comparar  diferentes  desfechos  neonatais  de  acordo  com  as  diferentes  modalidades
de tratamentos  do  diabetes  mellitus  gestacional.
Métodos:  Trata-se  de  uma  coorte  retrospectiva.  A  populac¸ão  do  estudo  foi  composta  por  ges-
tantes com  diabetes  gestacional  atendidas  em  uma  maternidade  pública  desde  Julho  de  2010
a Agosto  de  2014.  Foram  incluídas  mulheres  com  idade  mínima  de  18  anos,  gestac¸ão  única  e
com critérios  para  diabetes  mellitus  gestacional.  Para  decisão  terapêutica  foram  considera-
dos glicemias,  circunferência  abdominal  fetal,  índice  de  massa  corporal  e  idade  gestacional.
Os desfechos  neonatais  avaliados  foram:  via  de  parto,  prematuridade,  relac¸ão  do  peso  com
idade gestacional,  Apgar  no  1◦ e  5◦ minuto  e  necessidade  de  internac¸ão  em  unidade  de  terapia
intensiva.
Resultados:  A  amostra  foi  composta  por  705  gestantes.  Os  desfechos  neonatais  foram  analisados
com base  na  terapêutica  recebida.  Mulheres  tratadas  com  metformina  tiveram  menor  chance
de terem  ﬁlhos  pequenos  para  a  idade  gestacional  (IC  95%:  0,09-0,66)  e  maior  chance  de  terem
um ﬁlho  adequado  para  a  idade  gestacional  (IC  95%:  1,12-3,94).  A  gestante  tratada  com  insulina
teve menor  chance  de  ter  um  ﬁlho  prematuro  (IC  95%:  0,02-0,78).  O  tratamento  feito  com  a
associac¸ão de  insulina  e  metformina  resultou  em  maior  chance  de  um  recém-nascido  grande
para a  idade  gestacional  (IC  95%:  1,14-11,15)  e  menor  chance  de  prematuridade  (IC  95%:  0,01-
0,71). A  modalidade  de  tratamento  não  interferiu  na  via  de  parto,  Apgar  e  internac¸ão  em  terapia
intensiva.
Conclusões:  O  pediatra  na  sala  de  parto  pode  esperar  diferentes  desfechos  para  o  ﬁlho  de  mãe
diabética,  com  base  no  tratamento  recebido.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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the  hospital  were  included.ntroduction
ccording  to  a  Latin  American  multicentric  study,  ges-
ational  diabetes  mellitus  (GDM)  is  the  most  prevalent
etabolic  disorder  during  pregnancy.1 It  occurs  in  women
hose  pancreatic  function  is  insufﬁcient  to  overcome  the
nsulin  resistance  due  to  the  secretion  of  diabetogenic  hor-
ones  by  the  placenta.2 In  Brazil,  the  estimated  prevalence
f  GDM  varies  from  2.4%  to  7.2%.3
Both  the  mother  and  baby  are  affected  by  GDM,  as
oth  have  a  risk  of  developing  undesirable  outcomes.4 GDM
ffects  the  newborn  as  it  increases  the  chance  of  macroso-
ia,  fetal  distress,  metabolic  disorders,  hyperbilirubinemia,
rowth  imbalance,  and  other  complications.5 In  order  to
inimize  the  consequences,  it  is  necessary  that  the  disease
s  diagnosed  and  treated  early,  because  the  outcomes  are
lso  related  to  the  onset  and  duration  of  glucose  intoler-
nce,  as  well  as  the  severity  of  GDM.5
Insulin  has  been  used  as  the  standard  treatment  for  GDM
or  a  long  time.  However,  researchers  have  demonstrated
he  safety  of  oral  hypoglycemic  agents,  such  as  metformin,
n  the  initial  treatment  when  diet  alone  is  not  enough  to
chieve  the  desired  glucose  levels.6,7
Studies  that  compared  the  use  of  metformin  and  insulin
n  the  management  of  GDM  demonstrated  beneﬁts  with  the
se  of  oral  hypoglycemic  agents,  such  as  fewer  prema-
ure  births  and  cesarean  deliveries,  reduction  in  maternal
eight  gain,  and  fewer  adverse  neonatal  outcomes,  such  as Oacrosomia,6,8 hypoglycemia,  jaundice,  and  admission  to
pecial  neonatal  care  services.9
Thus,  the  study  aimed  to  compare  different  neonatal  out-
omes  according  to  the  different  treatment  modalities  used
n  the  management  of  GDM.
ethods
his  was  a  retrospective  cohort  study  based  on  the  analysis
f  medical  records,  carried  out  from  July  2010  to  August
014.  The  study  sample  was  chosen  by  convenience;  the
opulation  comprised  pregnant  women  with  GDM  treated  at
 high-risk  pregnancy  outpatient  clinic  of  a  public  mater-
ity  hospital.  The  project  was  approved  by  the  Research
thics  Committee  of  Hospital  Regional  Hans  Dieter  Schmidt,
oinville,  SC,  Brazil.
The  study  included  all  women  aged  ≥18  years  with  a
ingleton  pregnancy  and  who  met  the  criteria  for  GDM.10
he  diagnosis  of  GDM  was  made  based  on  the  oral  glucose
olerance  test.  The  presence  of  at  least  one  of  the  three
ollowing  criteria  conﬁrmed  the  diagnosis:  fasting  glucose
92  mg/dL,  blood  glucose  within  the  ﬁrst  hour  ≥180  mg/dL,
nd  glucose  levels  in  the  second  hour  ≥153  mg/dL.11 Women
hose  babies  had  no  malformations,  who  were  followed-up
t  the  outpatient  clinic,  and  whose  delivered  occurred  atCases  of  intrauterine  death  (n  =  3)  were  excluded.
f  these,  two  were  part  of  the  group  treated  with  a
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Table  1  General  characteristics  of  the  pregnant  women
(n =  705).
Variable  Mean  Standard
deviation
Age  30.58  6.34
Number  of  gestations  2.65  1.67
Pre-gestational  BMI  29.34  6.17
Gestational  agea 28.53  7.09
Fasting  glycemiab 89.23  13.65
Post-prandial  glycemiac 117.08  17.57
BMI, body mass index.
a Gestational age at the ﬁrst consultation in a gestational dia-
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chance  of  having  hypertensive  disease  of  pregnancy  (AOR
2.38  [1.07--5.28])  when  compared  with  those  under  the  diet
treatment.  The  other  GDM  treatments  showed  no  difference
in  relation  to  this  maternal  outcome.
Table  2  General  characteristics  of  the  newborns  (n  =  705).
Variables  Absolute  number  %
Type  of  delivery
Vaginal  338  47.9
Cesarean  section  367  52.1
Gestational  age
Preterm  50  7.1
Full-term  654  92.7
Post-term  1  0.2
Weight
Macrosomia  (≥4000  g)  13  1.9
Normal  weight  (2500--3999  g)  677  96
Low weight  (<2500  g)  15  2.1
Weight vs.gestational  age
SGA  (<P10)  51  7.2
AGA (between  P10  and  P90)  540  76.6
LGA (>P90)  114  16.2
Apgar 1′
Low  (<7)  40  5.7
Apgar 5′
Low  (<7)  8  1.1
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combination  of  metformin  and  insulin  and  one  had  been
treated  with  diet  alone.
The  ﬁrst  follow-up  consultation  of  diabetic  patients  usu-
ally  involves  obstetrical  ultrasound  and  routine  screening
for  GDM.  Furthermore,  the  pregnant  women  also  attended
a  welcome  lecture  with  a  nutritionist  and  a  physical  ther-
apist,  in  order  to  receive  information  regarding  lifestyle
changes  (diet  and  physical  exercise).  Then,  blood  glucose
was  measured  twice  on  consultation  day  (fasting  and  1  h
after  breakfast)  and  once  per  month  at  four  different  times
(fasting  and  1  h  after  the  start  of  each  meal).  The  interval
between  consultations  was  of  15--21  days.
The  blood  glucose  measurements  (fasting  and  postpran-
dial),  fetal  abdominal  circumference,  body  mass  index
(BMI),  and  gestational  age  were  considered  for  the  therapeu-
tic  decision-making.  Diet  therapy  was  recommended  to  all
pregnant  women.  In  mild  cases  of  GDM,  the  choice  of  ther-
apy  was  metformin.  When  no  glycemic  control  was  achieved
with  a  maximum  dose  of  metformin  (2.5  g),  it  was  associated
with  insulin  therapy;  insulin  therapy  was  promptly  started  in
more  severe  cases,  without  an  attempt  to  use  metformin.
GDM  cases  were  considered  severe  when  fetal  abdominal
circumference  was  >90th  percentile  and  maternal  fasting
glucose  was  >100  mg/dL  and  postprandial  (1  h)  >  140  mg/dL.
The  collected  data  related  to  the  women  were  full  name,
date  of  last  menstrual  period,  probable  date  of  delivery,  ges-
tational  age,  number  of  vaginal  deliveries,  cesarean  sections
and  miscarriages,  pre-pregnancy  weight  and  height,  results
of  oral  glucose  tolerance  test,  treatment  used,  and  blood
glucose  level.
After  birth,  the  medical  records  of  the  children  born  to
diabetic  mothers  were  analyzed  in  order  to  collect  informa-
tion  about  type  of  delivery,  gestational  age  at  birth,  birth
length  and  weight,  Apgar  score  at  the  ﬁrst  and  ﬁfth  min-
utes,  morphology,  and  admission  to  the  neonatal  intensive
care  unit  (NICU).
The  collected  data  were  stored  in  a  Microsoft  Excel  2013
(Microsoft®,  USA)  spreadsheet.  All  the  information  obtained
was  analyzed  using  SPSS  (IBM  Corp.  Released  2012.  IBM
SPSS  Statistics  for  Windows,  Version  21.0.  USA).  Means  and
standard  deviations  were  calculated  for  the  quantitative
variables,  whereas  absolute  and  relative  frequencies  were
used  for  qualitative  variables.  Binomial  logistic  regression
models  were  constructed  to  assess  the  inﬂuence  of  differ-
ent  therapies  on  neonatal  outcomes  and  adjust  the  effect
of  confounding  variables.  95%  conﬁdence  intervals  (95%  CI)
were  established  and  p  values  <0.05  were  considered  signif-
icant.
Results
The  study  sample  consisted  of  705  pregnant  women  diag-
nosed  with  GDM  and  their  respective  babies.  After  the
medical  records  were  analyzed,  the  participants  were
grouped  into  four  treatment  groups:  (1)  diet,  (2)  metformin,
(3)  insulin,  and  (4)  metformin  +  insulin.
Table  1  shows  the  general  characteristics  of  the  study
participants.  Brieﬂy,  the  patients  had  a  mean  age  of  30.6
years  (SD  ±  6.34)  and  mean  number  of  pregnancies  of  2.65
(SD  ±  1.67).  Cesarean  section  was  the  type  of  delivery
in  52.1%  of  the  cases.  Regarding  GDM  treatment,  mostbetes mellitus outpatient clinic.
b Mean values obtained during gestation.
c Mean values obtained during gestation.
regnant  women  were  prescribed  diet  therapy  as  the  treat-
ent  of  choice  (41.6%);  35.5%  of  the  women  were  treated
ith  metformin,  15%  with  insulin,  and  the  remainder  with  a
etformin  and  insulin  association  (7.9%).
Hypertensive  disease  of  pregnancy  was  present  in  72
atients.  Twenty-six  mothers  were  treated  with  metformin,
6  with  diet  therapy,  15  with  insulin  alone,  and  15  with  the
ssociation  of  insulin  and  metformin.  Those  who  received
he  combination  of  metformin  and  insulin  had  a  higher36  5.1
SGA, small for gestational age; AGA, adequate for gestational
age; LGA, large for gestational age; ICU, intensive care unit.
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Table  3  Multivariate  analysis  of  neonatal  outcomes  according  to  type  of  gestational  diabetes  mellitus  therapy  (n  =  705).
Outcome  Therapeutic  modality  n  (%)  Crude  OR  (95%  CI)  p  Adjusted  ORa (95%  CI)  p
Cesarean
section
Diet  137  (37.3%)  --  --  --  --
Metformin 128  (34.8%)  1.221  (0.871--1.171)  0.247  0.665  (0.370--1.194)  0.172
Insulin 68  (18.5%)  2.066  (1.306--3.268)  0.002  1.426  (0.629--3.231)  0.395
Metformin +  insulin  34  (9.2%)  1.784  (0.996--3.197)  0.052  0.891  (0.305--2.607)  0.833
Preterm
birth
Diet 28  (56%)  --  --  --  --
Metformin 17  (34%) 0.694  (0.370--1.299) 0.253  0.429  (0.173--1.064)  0.068
Insulin 3  (6%) 0.276  (0.082--0.926) 0.037 0.133  (0.023--0.789)  0.026
Metformin +  insulin 2  (4%) 0.351  (0.081--1.516) 0.161 0.105  (0.015--0.713) 0.021
SGA Diet 34  (66.6%)  --  --  --  --
Metformin 13  (25.4%)  0.420  (0.216--0.814)  0.010  0.253  (0.096--0.666)  0.005
Insulin 3  (5.8%)  0.222  (0.067--0.738)  0.014  0.179  (0.027--1.197)  0.076
Metformin +  insulin  1  (1.9%)  0.139  (0.019--1.033)  0.054  0.191  (0.017--2.163)  0.181
AGA Diet 230  (42.59%)  --  --  --  --
Metformin 204  (37.77%)  1.267  (0.828--1.939)  0.276  2.103  (1.121--3.945)  0.021
Insulin 73  (13.51%)  0.618  (0.377--1.015)  0.057  1.306  (0.579--2.947)  0.520
Metformin +  insulin  33  (6.11%)  0.401  (0.220--0.731)  0.003  0.612  (0.230--1.634)  0.327
LGA Diet 30  (26.31%)  --  --  --  --
Metformin 32  (28.07%)  1.293  (0.761--2.195)  0.342  0.891  (0.375--2.115)  0.793
Insulin 30  (26.31%)  3.461  (1.963--6.100)  0.000  1.591  (0.590--4.290)  0.358
Metformin +  insulin  22  (19.29%)  5.673  (2.944--10.931)  0.000  3.567  (1.141--11.150)  0.029
Apgar
1′ <  7
Diet  15  (37.5%)  --  --  --  --
Metformin 17  (42.5%)  1.38  (0.664--2.778)  0.402  1.742  (0.516--5.878)  0.371
Insulin 6  (15%)  1.112  (0.40--2.945)  0.831  0.564  (0.098--3.245)  0.521
Metformin +  insulin 2  (5%)  0.686  (0.153--3.088)  0.624  0.711  (0.091--5.543)  0.745
Apgar
5′ <  7
Diet  5  (62.5%)  --  --  --  --
Metformin 1  (12.5%)  0.291  (0.032--2.624)  0.271  0.537  (0.025--11.527)  0.691
Insulin 0  0  0.989  0  0.998
Metformin +  insulin 2  (25%)  2.676  (0.478--14.975)  0.263  2.111  (0.061--73.137)  0.680
ICU Diet 15  (41.66%)  --  --  --  --
Metformin 10  (27.77%)  0.775  (0.342--1.758)  0.543  0.625  (0.178--2.196)  0.464
Insulin 3  (8.33%) 0.540  (0.153--1.903)  0.338  0.079  (0.005--1.150)  0.063
Metformin +  insulin 8  (22.22%) 3.089  (1.242--7.682) 0.015  1.156  (0.215--6.212)  1.156
OR, odds ratio; CI, conﬁdence interval; SGA, small for gestational age; AGA, adequate for gestational age; LGA, large for gestational
age; ICU, intensive care unit.
a Adjusted OR for the following variables: maternal age, maternal body mass index, number of pregnancies, type of delivery, gestational
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Regarding  the  characteristics  of  the  newborns  (Table  2),
he  mean  GA  at  delivery  was  38.6  weeks  (SD  ±  1.38).  Thirty-
our  babies  were  preterm  (4.8%);  40  (5.6%)  had  low  Apgar
core  at  the  ﬁrst  minute  and  eight  (1.1%)  had  low  Apgar
core  at  the  ﬁfth  minute.  A  total  of  114  (16.1%)  newborns
ere  large  for  gestational  age  and  51  (7.2%)  were  born  small
or  gestational  age.  Thirty-six  (5.1%)  newborns  needed  NICU
dmission.
The  neonatal  outcomes  were  analyzed  based  on  the  GDM
herapy  used  (Table  3),  taking  into  account  that  the  treat-
ents  were  compared  with  the  diet  therapy.
The  type  of  treatment  did  not  affect  the  outcome  type
f  delivery,  Apgar  scores  at  the  ﬁrst  and  ﬁfth  minutes,  and
eed  for  NICU  admission.
Pregnant  women  who  were  treated  with  metformin  had
 lower  chance  of  having  a  small  for  gestational  age  (SGA)
hild  and  also  had  slightly  over  twice  the  chance  of  hav-
ng  a  baby  with  adequate  weight  for  gestational  age  (AGA).
others  who  received  insulin  treatment  had  a  lower  chance
3
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m
n glucose, and fetal abdominal circumference (considered between
hat  their  children  would  be  born  preterm.  Similarly,  moth-
rs  treated  with  the  combination  of  metformin  and  insulin
ere  also  less  likely  to  have  preterm  children.  In  addition,
omen  treated  with  this  combination  therapy  had  more  than
hree  times  the  chance  of  having  a  large  for  gestational  age
LGA)  child.
iscussion
he  present  study  evaluated  different  neonatal  outcomes
ccording  to  the  treatment  of  choice  for  GDM.  In  the  present
opulation,  16.2%  of  newborns  were  classiﬁed  as  LGA.  Treat-
ent  with  the  association  of  insulin  and  metformin  was
esponsible  for  a  3.5-fold  higher  chance  of  an  LGA  child  (AOR
.56  [1.14--11.15]).  The  rate  of  SGA  newborns  was  7.2%,  and
he  chance  was  lower  in  the  group  of  women  treated  with
etformin  (AOR  0.25  [0.09--0.66]).  The  percentage  of  AGA
ewborns  was  76.6%;  the  use  of  metformin  was  associated
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with  a  two-fold  higher  chance  of  AGA  newborns  (AOR  2.10
[1.12--3.94]).
The  percentage  of  preterm  infants  was  7.1%.  Those
treated  with  insulin  had  a  lower  chance  for  this  out-
come  (AOR  0.13  [0.023--0.78]),  as  well  as  those  treated
with  a  combination  of  insulin  and  metformin  (AOR  0.10
[0.01--0.71]).  NICU  admission  rate  was  5.1%;  the  treatment
modalities  did  not  affect  the  need  for  it.  The  percentage
of  cesarean  deliveries  was  52.1%,  and  the  GDM  treatment
modalities  did  not  affect  the  type  of  delivery.  There  was  no
increased  chance  of  low  Apgar  score,  both  at  the  ﬁrst  and
the  ﬁfth  minutes,  according  to  the  therapy  used.
The  present  study  is  important,  because  although  insulin
is  considered  the  standard  classical  treatment  for  the  dis-
ease,  metformin  has  demonstrated  good  results  in  GDM
control  and  appears  to  attenuate  the  possible  neonatal
outcomes.6,7
The  physicians  responsible  for  pregnant  women  with  GDM
need  to  be  aware  of  the  maternal  and  neonatal  risks  related
to  this  metabolic  disorder.12 One  of  the  most  common
complications  of  GDM  is  an  LGA  child.12 When  the  newborn
is  classiﬁed  as  LGA,  in  addition  to  the  fact  that  the  birth
is  associated  with  increased  risk  of  obstetric  traumas  and
shoulder  dystocia,  immediate  effects  such  as  hypoglycemia
and  respiratory  dysfunction  may  also  occur.12
In  the  present  study,  16.2%  of  newborns  were  classiﬁed
as  LGA.  In  the  literature,  this  percentage  ranges  from  13.4
to  30%.13--16 Patients  who  received  the  association  of  insulin
and  metformin  had  a  3.5-fold  higher  risk  of  having  an  LGA
baby.  There  was  no  difference  for  the  other  treatments.
The  literature  showed  higher  rates  of  LGA  births  in  women
treated  with  insulin  when  compared  with  those  treated  with
metformin  or  diet  therapy.6
Among  the  perinatal  complications  of  an  LGA  newborn,
are  noteworthy  the  increased  risk  of  meconium  aspiration,
clavicle  fracture,  perinatal  hypoxia,  hypoglycemia,  hyper-
bilirubinemia,  transient  tachypnea,  brachial  plexus  injury,
shoulder  dystocia,  and  even  neonatal  death.17 These  babies
were  also  at  increased  risk  at  the  moment  of  treatment
choice,  which  was  more  aggressive  due  to  the  fetal  char-
acteristics  observed  during  prenatal  care.
An  intensive  therapy  for  GDM  may  result  in  a  decrease
of  fetal  weight,  preventing  LGA  newborns.  However,
one  consequence  is  the  increase  in  the  number  of  SGA
newborns.18 Such  disorders  are  also  related  to  early  neonatal
complications  and  diseases  in  adulthood.18,19
In  this  study,  the  incidence  of  SGA  infants  was  7.2%,  while
in  the  literature  it  ranged  from  3%  to  10.5%.19,20 The  chance
of  having  an  SGA  newborn  was  lower  in  the  group  of  women
treated  with  metformin.  The  study  by  Goh  et  al.  showed  no
difference  for  the  SGA  outcome  according  to  the  different
treatments.6
Being  SGA  is  as  unfavorable  as  being  LGA,  since  both  are
associated  with  higher  morbidity  and  mortality  in  the  short-
and  long-term.  Therefore,  preventing  the  occurrence  of  SGA
is  as  important  as  preventing  that  of  LGA.20 In  a  select  group
of  pregnant  women,  when  there  is  indirect  evidence  of  fetal
hyperinsulinization  at  the  ultrasound,  the  drug  dose  could  be
reduced.
For  that  purpose,  it  might  be  necessary  to  consider  the
fetal  weight  estimated  by  the  ultrasound  in  the  therapeu-
tic  option  of  patients  treated  with  metformin,  as  there  was
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 higher  risk  of  SGA.  Thus,  an  approach  based  on  ultra-
ound  parameters  can  provide  a  more  ﬂexible  therapeutic
odel  for  those  patients  whose  newborn  weight  estimated
y  the  ultrasound  is  reduced  and  therefore,  the  dose  can  be
ecreased.20
The  quality  of  the  treatment  provided  to  diabetic
regnant  women  has  a  direct  effect  on  the  newborn  weight
lassiﬁcation.  Considering  that  AGA  is  the  treatment  goal,
reatment  success  can  be  assessed  by  this  parameter.  In  the
resent  study,  the  incidence  of  AGA  infants  was  76.6%.  The
iterature  reports  that  AGA  rates  are  around  86.6%.20 Met-
ormin  was  shown  to  be  very  satisfactory  in  this  regard,  as
ts  use  was  associated  with  a  two-fold  higher  chance  of  AGA
ewborns.
Spontaneous  and  medically  indicated  preterm  birth
ccurs  more  often  in  diabetic  pregnant  women  than  in  their
on-diabetic  peers.5 Preterm  newborns  have  a  higher  rate
f  infant  mortality  and  morbidity  when  compared  with  chil-
ren  born  at  term.  Short-term  complications  of  prematurity
re  related  to  the  cardiovascular  and  respiratory  systems21;
isorders  such  as  cerebral  palsy  may  occur  as  a  long-term
eurodevelopmental  complication.22 Preterm  newborns  are
ore  likely  to  develop  hypertension,  obesity,  and  cardiovas-
ular  disease  in  adulthood.23
The  percentage  of  preterm  infants  in  this  study  was  7.1%.
n  other  studies,  the  percentage  of  preterm  infants  ranged
rom  4%  to  16%.5,6 The  present  study  showed  that  preterm
nfants  are  more  commonly  born  to  mothers  treated  with
nsulin  or  the  combination  of  metformin  and  insulin  than
o  those  under  diet  therapy.  These  data  corroborate  the
esults  of  a  similar  study.6 Furthermore,  the  comparison  of
he  prematurity  outcome  between  the  diet  and  metformin
herapies  showed  no  signiﬁcant  difference,6 similarly  to  the
resent  study.
Given  the  various  complications  to  which  the  child  of  a
other  with  GDM  is  predisposed,  sometimes  a  more  inten-
ive  therapy  is  necessary.  Reasons  for  NICU  admission  include
ongenital  abnormalities  (such  as  cardiovascular  malforma-
ions),  prematurity,  perinatal  asphyxia,  respiratory  distress,
nd  metabolic  complications  (hypoglycemia,  hypocalcemia,
olycythemia,  and  hyperbilirubinemia),  among  others.5 In
he  present  study,  the  NICU  admission  rate  was  5.1%.  This
alue  corroborates  other  values  found  in  the  literature
2%--6%),1,20 but  is  dissimilar  from  others,  in  which  the  need
or  NICU  admission  ranged  from  15%6 to  23.5%.5
In  the  present  study,  the  type  of  treatment  did  not  affect
he  need  for  NICU  admission,  while  other  authors  found  that
nfants  born  to  women  treated  with  insulin  had  higher  rates
f  NICU  admission  when  compared  with  pregnant  women
ho  received  treatment  with  metformin  or  diet  therapy.6
Since  pregnant  diabetic  women  have  a  higher  risk  of  hav-
ng  LGA  children,  the  indication  for  cesarean  deliveries  may
ncrease.  The  purpose  of  this  type  of  delivery  is  to  prevent
rauma  during  the  birth  of  infants  with  estimated  weight
4500  g.17
The  percentage  of  cesarean  deliveries  in  the  study  was
2.1%.  This  is  similar  to  the  percentage  of  cesarean  sec-
ions  in  other  Brazilian  studies,24,25 but  rates  are  lower  in
he  international  scenario.6,26 This  difference  may  be  due
o  the  dissemination  of  cesarean  practice  in  Brazil,  unlike
ther  countries.  GDM  treatment  modalities  did  not  affect
he  type  of  delivery.  In  contrast,  another  study  showed  that
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he  cesarean  section  was  more  prevalent  in  women  treated
ith  insulin.6
The  Apgar  score  is  used  as  an  evaluation  method  of  the
ewborn’s  birth  quality  between  the  ﬁrst  and  ﬁfth  minutes
f  life.27 It  assesses  the  immediate  adjustment  of  the  new-
orn  to  extrauterine  life,  analyzing  the  baby’s  vitality.  It
onsists  of  the  evaluation  of  ﬁve  items  of  the  newborn’s
hysical  examination:  heart  rate,  respiratory  effort,  muscle
one,  reﬂex  irritability,  and  skin  color.27
The  Apgar  score  at  the  ﬁrst  minute  is  considered  a
iagnosis  of  the  present  situation,  an  index  that  can  rep-
esent  a  sign  of  asphyxiation  and  the  need  for  mechanical
entilation.27 As  for  the  Apgar  score  at  the  ﬁfth  minute,  it
s  considered  to  be  more  accurate,  leading  to  the  progno-
is  of  neurological  health  and  outcomes  such  as  neurological
equelae  or  death.27
In  the  present  population,  similarly  to  other  studies,5,26
here  was  no  increased  risk  of  low  Apgar,  either  at  the  ﬁrst
r  the  ﬁfth  minute,  according  to  the  therapy  used.  This  may
emonstrate  the  success  in  the  care  provided  to  newborns
f  diabetic  mothers.28
The  outcomes  of  cesarean  delivery  and  Apgar  scores  at
he  ﬁrst  and  ﬁfth  minutes  and  need  for  NICU  admission  were
ot  different  between  the  treatments.
Due  to  the  methodology  used  in  the  study,  there
ere  some  limitations  to  the  comparison  of  results,  since
ew  studies  used  the  same  method.  Another  point  to  be
ighlighted  is  the  heterogeneity  of  participants  in  each  ther-
peutic  modality  group,  because  each  treatment  was  aimed
t  a  distinct  proﬁle  of  pregnant  women.
It  can  be  concluded  that  the  pediatrician  in  the  delivery
oom  can  expect  different  outcomes  for  children  born  to
iabetic  mothers  based  on  the  treatment  that  she  received
uring  pregnancy.  Women  treated  with  metformin  are  less
ikely  to  have  SGA  children  and  more  likely  to  have  an  AGA
hild.  A  pregnant  woman  who  was  treated  with  insulin  has
 lower  chance  of  having  a  preterm  child.  If  the  GDM  treat-
ent  of  was  a  combination  of  insulin  and  metformin,  there
s  a  higher  chance  of  the  child  being  born  LGA  and  a  lower
hance  of  being  preterm.
For  the  other  assessed  outcomes  (type  of  delivery,  Apgar
core,  and  need  for  NICU  admission),  there  were  no  differ-
nces  between  treatment  modalities.
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